KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Working Capital Changes (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Working Capital Changes for 16 consecutive years, with -$28.4 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 405.68% to -$28.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.0 million through Dec 2025, up 715.35% year-over-year, with the annual reading at $33.0 million for FY2025, 715.35% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$28.4 million at Halozyme Therapeutics, down from $20.3 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $43.5 million in Q2 2024, with the low at -$38.5 million in Q3 2024.
  • Average Other Working Capital Changes over 5 years is $1.6 million, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Other Working Capital Changes surged 4189.4% in 2023, then plummeted 21890.29% in 2024.
  • Over 5 years, Other Working Capital Changes stood at $12.6 million in 2021, then tumbled by 234.27% to -$16.9 million in 2022, then skyrocketed by 90.99% to -$1.5 million in 2023, then crashed by 270.05% to -$5.6 million in 2024, then tumbled by 405.68% to -$28.4 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$28.4 million, $20.3 million, and $36.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.